Learn About Temporal Arteritis

What is the definition of Temporal Arteritis?

Giant cell arteritis is inflammation and damage to the blood vessels that supply blood to the head, neck, upper body and arms. It is also called temporal arteritis.

Save information for later
Sign Up
What are the alternative names for Temporal Arteritis?

Arteritis - temporal; Cranial arteritis; Giant cell arteritis

What are the causes of Temporal Arteritis?

Giant cell arteritis affects medium-to-large arteries. It causes inflammation, swelling, tenderness, and damage to the blood vessels that supply blood to the head, neck, upper body, and arms. It most commonly occurs in the arteries around the temples (temporal arteries). These arteries branch off from the carotid artery in the neck. In some cases, the condition can occur in medium-to-large arteries in other places in the body as well.

The cause of the condition is unknown. It is believed to be due in part to a faulty immune response. The disorder has been linked to some infections and to certain genes.

Giant cell arteritis is more common in people with another inflammatory disorder known as polymyalgia rheumatica. Giant cell arteritis almost always occurs in people over age 50. It is most common in people of northern European descent. The condition may run in families.

What are the symptoms of Temporal Arteritis?

Some common symptoms of this problem are:

  • New throbbing headache on one side of the head or the back of the head
  • Tenderness when touching the scalp

Other symptoms may include:

  • Jaw pain that occurs when chewing
  • Pain in the arm after using it
  • Muscle aches
  • Pain and stiffness in the neck, upper arms, shoulder, and hips (polymyalgia rheumatica)
  • Weakness, excessive tiredness
  • Fever
  • General ill feeling

Problems with eyesight may occur, and at times may begin suddenly. These problems include:

  • Blurred vision
  • Double vision
  • Sudden reduced vision (blindness in one or both eyes)
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Temporal Arteritis?

Getting prompt treatment can help prevent severe problems such as blindness.

When giant cell arteritis is suspected, you will receive corticosteroids, such as prednisone, by mouth. These medicines are often started even before a biopsy is done. You may also be told to take aspirin.

Most people begin to feel better within a few days after starting treatment. The dose of corticosteroids will be cut back very slowly. However, you will need to take medicine for 1 to 2 years.

If the diagnosis of giant cell arteritis is made, in most people a biologic medicine called tocilizumab will be added. This medicine reduces the amount of corticosteroids needed to control the disease.

Long-term treatment with corticosteroids can make bones thinner and increase your chance of a fracture. You will need to take the following steps to protect your bone strength.

  • Avoid smoking and excess alcohol intake.
  • Take extra calcium and vitamin D (based on your provider's advice).
  • Start walking or other forms of weight-bearing exercises.
  • Have your bones checked with a bone mineral density (BMD) test or DEXA scan.
  • Take a bisphosphonate medicine, such as alendronate (Fosamax), as prescribed by your provider.
Who are the top Temporal Arteritis Local Doctors?
Learn about our expert tiers
Learn more
What is the outlook (prognosis) for Temporal Arteritis?

Most people make a full recovery, but treatment may be needed for 1 to 2 years or longer. The condition may return at a later date.

Damage to other blood vessels in the body, such as aneurysms (ballooning of the blood vessels), may occur. This damage can lead to a stroke in the future.

When should I contact a medical professional for Temporal Arteritis?

Call your provider if you have:

  • Throbbing headache that does not go away
  • Loss of vision
  • Other symptoms of temporal arteritis

You may be referred to a specialist who treats temporal arteritis.

How do I prevent Temporal Arteritis?

There is no known prevention.

Carotid artery anatomy
What are the latest Temporal Arteritis Clinical Trials?
Study of T Lymphocytes in the Mucosa in Giant-cell Arteritis (GCA) - Giant Cell Arteritis and Mucosal Associated Invariant T Cells

Summary: Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. Corticosteroid therapy is the reference treatment for GCA. This treatment is highly effective but must be maintained for 12 to 24 months to avoid relapses, which causes the onset of numerous adverse effects in this elderly population. Currently clinicians have no way to estimate this risk of relapse during the treatment of ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Head-to-head Comparison of Ultrasound Versus Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis

Summary: Giant cell arteritis - Optimization of diagnostics

What are the Latest Advances for Temporal Arteritis?
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
Tocilizumab for giant cell arteritis.
Tired of the same old research?
Check Latest Advances
Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis?
Who are the sources who wrote this article ?

Published Date: January 31, 2021
Published By: Diane M. Horowitz, MD, Rheumatology and Internal Medicine, Northwell Health, Great Neck, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636-643. PMID: 29358285 pubmed.ncbi.nlm.nih.gov/29358285/.

Hellmann DB. Giant cell arteritis, polymyalgia rheumatica, and Takayasu's arteritis. In: Firestein GS, Budd RC, Gabriel SE, Koretzky GA, McInnes IB, O'Dell JR, eds. Firestein & Kelley's Textbook of Rheumatology. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 93.

James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM. Cutaneous vascular diseases. In: James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM, eds. Andrews' Diseases of the Skin: Clinical Dermatology. 13th ed. Philadelphia, PA: Elsevier; 2020:chap 35.

Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). 2018;57(suppl_2):ii32-ii42. PMID: 29982778 pubmed.ncbi.nlm.nih.gov/29982778/.

Matza MA, Unizony SH. Polymyalgia rheumatica and giant cell arteritis. In: Kellerman RD, Rakel DP, eds. Conn's Current Therapy 2021. Philadelphia, PA: Elsevier; 2021:975-977.

Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. PMID: 28745999 pubmed.ncbi.nlm.nih.gov/28745999/.

Tamaki H, Hajj-Ali RA. Tocilizumab for giant cell arteritis - a new giant step in an old disease. JAMA Neurol. 2018;75(2):145-146. PMID: 29255889 pubmed.ncbi.nlm.nih.gov/29255889/.